Advancing Brain Cancer Imaging
TrivarX is developing Stabl-Im, an imaging-focused platform that explores the use of stable isotopes with MRI to generate additional biological information about brain cancers and metastases – without the use of ionising radiation.
Funding secured
New funding secured to support Stabl-Im development activities.
Clinical development planning
A clinical feasibility study is in planning to evaluate safe operating parameters, imaging performance and reproducibility.
Radiation-Free Approach
Designed to investigate tumour biology using stable isotopes and MRI, without radioactive tracers
What we Do
TrivarX is a biotechnology company focused on developing medical imaging technologies for oncology applications.
The Company’s lead program, Stabl-Im, is investigating whether stable isotope labelling combined with MRI can provide additional information about tumour biology, including features associated with cell turnover and treatment-related changes.
The initial focus is on brain cancers and brain metastases, where distinguishing active tumour from treatment effect or other tissue changes can be clinically challenging.
Stabl-Im is being developed as a potential complement to existing imaging approaches, with the aim of supporting more informed detection, monitoring and treatment response assessment.
TrivarX is progressing the program toward clinical development, with activities underway across supply, formulation, regulatory strategy, imaging methodology and finalising clinical study design.